As new components of the Immuno-Oncology Translation Network (IOTN), the Immuno-engineering to Improve Immunotherapy (i3) Centers will be comprised of multi-disciplinary teams focused on developing and employing engineered immunotherapy approaches to design more durable, widely accessible, and less toxic immunoprevention and immunotherapy strategies.

Immuno-engineering to Improve Immunotherapy (i3) Centers will incorporate innovative engineering solutions to accelerate the preclinical development of immunotherapeutic and immunopreventive interventions that are more effective, safer, and that could benefit a wider patient population - including pediatric, elderly, immunodeficient, underserved, and rare cancer patient populations.